Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 140 of 1,261
  1. WO 2024023766

    POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K

    BERLIN CHEMIE AG [DE] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  2. CA 3259243

    POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2

    RYVU THERAPEUTICS S A [PL] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  3. CA 3263005

    POLYPEPTIDES SE LIANT À UN ÉPITOPE SPÉCIFIQUE DU RÉCEPTEUR FC NÉONATAL

    SANOFI SA [FR] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  4. CA 3259252

    POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3

    RYVU THERAPEUTICS S A [PL] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  5. CA 3256289

    MÉTHODES PERMETTANT DE FAVORISER LA CROISSANCE DE RATTRAPAGE SAINE

    ABBOTT LAB [US] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  6. US 11883420

    Sting agonists for treating bladder cancer and solid tumors

    VENENUM BIODESIGN, LLC · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  7. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  8. US 11883381

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  9. US 11883386

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  10. US 11884731

    Vedolizumab for the treatment of fistulizing Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  11. US 11883223

    Hepatic inflammation analysis with dynamic PET

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  12. US 11884707

    Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  13. US 11884647

    Compounds and methods for targeting pathogenic blood vessels

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  14. US 11883535

    Liposomal particles, methods of making same and uses thereof

    Northwestern University · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  15. US 11883432

    Chimeric antigen receptor system with adaptable receptor specificity

    Century Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  16. US 11884657

    PI-kinase inhibitors with anti-infective activity

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  17. US 11883441

    Compositions and methods for inhibiting seizures

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  18. US 11884656

    Pyrrole derivatives as PLK1 inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  19. US 11883431

    T-cells modified to overexpress PHF19

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  20. US 11883433

    Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

    CELLENGENE INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  21. US 11884715

    Activin receptor type IIB variants and methods of use thereof

    Keros Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  22. US 11885817

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  23. US 11883383

    Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine

    VTV THERAPEUTICS LLC · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  24. US 11884944

    Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

    DENALI THERAPEUTICS INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.